Related Experiment Video
Updated: May 2, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
Natalia Buza1, Dana M Roque, Alessandro D Santin
1From the Departments of Pathology (Dr Buza) and Obstetrics, Gynecology, and Reproductive Sciences (Drs Roque and Santin), Yale University School of Medicine, New Haven, Connecticut; and the Gynecologic Oncology Program, Yale Cancer Center, New Haven, Connecticut (Dr Santin).
Context:
In the era of targeted cancer therapy, there is growing interest in developing novel therapeutic strategies against endometrial carcinoma, especially its most biologically aggressive variant, serous adenocarcinoma. Several publications have demonstrated that a significant proportion of uterine serous carcinomas show HER2 overexpression and/or amplification, suggesting that HER2 may be a promising therapeutic target. Case reports have already shown clinical response to trastuzumab, a humanized monoclonal immunoglobulin (Ig) G1 antibody against HER2, and patients are currently being enrolled in a multi-institutional prospective randomized trial to evaluate the therapeutic efficacy of trastuzumab.
Objective:
To review current data on HER2 testing and targeted therapy against HER2/neu in endometrial carcinoma.
Data Sources:
Review of the literature and personal experience of the authors.
Conclusions:
Parallel to the clinical studies, there is a need to develop standardized criteria for HER2 testing in endometrial carcinoma that reflect the unique biological and pathogenetic features of these tumors and correlate with clinical response to therapy. This article presents a comprehensive review of the current state of HER2-based therapy and HER2 testing in endometrial carcinoma.
Insights
HER2 is a promising target for endometrial carcinoma, particularly serous adenocarcinoma. Standardized HER2 testing is crucial for effective targeted therapy with drugs like trastuzumab.
Area of Science:
- Oncology
- Molecular Biology
- Therapeutics
Background:
- Endometrial carcinoma, especially serous adenocarcinoma, requires novel targeted therapies.
- HER2 overexpression/amplification is common in uterine serous carcinomas, identifying HER2 as a potential therapeutic target.
- Trastuzumab (a HER2-targeted antibody) has shown promising clinical responses in case reports.
Purpose of the Study:
- To review current data on HER2 testing methodologies.
- To summarize the efficacy of HER2-targeted therapy in endometrial carcinoma.
- To discuss the role of HER2/neu in endometrial cancer treatment.
Main Methods:
- Comprehensive literature review.
- Analysis of personal author experiences.
- Synthesis of existing data on HER2 testing and therapy.
Main Results:
- HER2 is a viable therapeutic target in endometrial carcinoma.
- Trastuzumab demonstrates potential clinical efficacy.
- Ongoing trials are evaluating trastuzumab's therapeutic value.
Conclusions:
- Standardized HER2 testing criteria are needed for endometrial carcinoma.
- Testing criteria should align with tumor biology and predict treatment response.
- This review provides a comprehensive overview of HER2-based therapy and testing in endometrial carcinoma.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...